<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Cognition Therapeutics Inc.</title>
    <link>https://www.biospace.com/employer/546926/cognition-therapeutics-inc</link>
    <description>Cognition Therapeutics Inc.</description>
    <language>en-US</language>
    <lastBuildDate>Wed, 18 Sep 2019 18:24:10 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/546926/cognition-therapeutics-inc.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook</title>
      <link>https://www.biospace.com/alzheimer-s-disease-insight-report-current-therapies-drug-pipeline-and-outlook</link>
      <dc:creator>Chelsea Weidman Burke, M.S.</dc:creator>
      <description>50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.</description>
      <pubDate>Wed, 18 Sep 2019 18:24:10 GMT</pubDate>
      <guid>https://www.biospace.com/alzheimer-s-disease-insight-report-current-therapies-drug-pipeline-and-outlook</guid>
    </item>
    <item>
      <title>Top 10 Pharm Country Companies to Receive NIH Funding in 2020</title>
      <link>https://www.biospace.com/top-10-pharm-country-companies-to-receive-nih-funding-in-2020</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.</description>
      <pubDate>Wed, 03 Mar 2021 16:03:38 GMT</pubDate>
      <guid>https://www.biospace.com/top-10-pharm-country-companies-to-receive-nih-funding-in-2020</guid>
    </item>
    <item>
      <title>Three New Nasdaq Tickers and MPM Capital Secures $850 Million to Impact Oncology</title>
      <link>https://www.biospace.com/three-companies-debut-on-the-nasdaq-mpm-capital-raises-whopping-850-million-for-fund</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.</description>
      <pubDate>Fri, 08 Oct 2021 13:53:20 GMT</pubDate>
      <guid>https://www.biospace.com/three-companies-debut-on-the-nasdaq-mpm-capital-raises-whopping-850-million-for-fund</guid>
    </item>
    <item>
      <title>Money on the Move: October 6 – 12</title>
      <link>https://www.biospace.com/money-on-the-move-october-6-12</link>
      <dc:creator>Kate Goodwin</dc:creator>
      <description>Investors are dropping dollars into the life sciences industry like the trees are dropping their leaves. Here’s who’s raking in the cash this week.</description>
      <pubDate>Wed, 13 Oct 2021 11:18:08 GMT</pubDate>
      <guid>https://www.biospace.com/money-on-the-move-october-6-12</guid>
    </item>
    <item>
      <title>Life Sciences IPO Scene Buzzing So Far in October</title>
      <link>https://www.biospace.com/life-sciences-ipo-scene-buzzing-so-far-in-october</link>
      <dc:creator>Ellen Camacho</dc:creator>
      <description>It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.</description>
      <pubDate>Wed, 13 Oct 2021 15:49:49 GMT</pubDate>
      <guid>https://www.biospace.com/life-sciences-ipo-scene-buzzing-so-far-in-october</guid>
    </item>
    <item>
      <title>Pursuit of Scientific Challenges Drives New CODA CSO Susan Catalano</title>
      <link>https://www.biospace.com/pursuit-of-scientific-challenges-drives-coda-s-new-cso-susan-catalano</link>
      <dc:creator>Gail Dutton</dc:creator>
      <description>Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.</description>
      <pubDate>Wed, 30 Mar 2022 13:39:47 GMT</pubDate>
      <guid>https://www.biospace.com/pursuit-of-scientific-challenges-drives-coda-s-new-cso-susan-catalano</guid>
    </item>
    <item>
      <title>Clinical Catch-Up: xBiotech, Exelixis, DermBiont Target Cancer</title>
      <link>https://www.biospace.com/clinical-catch-up-june-20-24</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.</description>
      <pubDate>Fri, 24 Jun 2022 15:46:54 GMT</pubDate>
      <guid>https://www.biospace.com/clinical-catch-up-june-20-24</guid>
    </item>
    <item>
      <title>Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease</title>
      <link>https://www.biospace.com/cognition-therapeutics-announces-publication-analyzing-biomarkers-of-synapse-damage-or-loss-to-support-future-therapeutic-development-efforts-in-alzheimer-s-disease</link>
      <description>Cognition Therapeutics, Inc. , a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the publication of an article titled, The Clinical Promise of Biomarkers of Synapse Damage or Loss in Alzheimer’s Disease , which reviews the foundational role of synapses in cognitive function and discusses available and experimental b</description>
      <pubDate>Tue, 17 Mar 2020 11:06:08 GMT</pubDate>
      <guid>https://www.biospace.com/cognition-therapeutics-announces-publication-analyzing-biomarkers-of-synapse-damage-or-loss-to-support-future-therapeutic-development-efforts-in-alzheimer-s-disease</guid>
    </item>
    <item>
      <title>Cognition Therapeutics Announces Change in Leadership</title>
      <link>https://www.biospace.com/cognition-therapeutics-announces-change-in-leadership</link>
      <description>Cognition Therapeutics, Inc. , a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Kenneth I. Moch has stepped down as president and chief executive officer to assume an advisory role. Lisa Ricciardi has transitioned from her position on the Cognition Board of Directors to become acting chief executive officer. Mr</description>
      <pubDate>Fri, 27 Mar 2020 11:06:03 GMT</pubDate>
      <guid>https://www.biospace.com/cognition-therapeutics-announces-change-in-leadership</guid>
    </item>
    <item>
      <title>Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium</title>
      <link>https://www.biospace.com/cognition-therapeutics-receives-75-8-million-nia-grant-for-540-patient-phase-2-study-of-ct1812-in-collaboration-with-the-alzheimer-s-clinical-trials-consortium</link>
      <description>Cognition Therapeutics, Inc. , a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected to total $75.8 million over five years to support a 540-patient Phase 2 study of CT1812 in indi</description>
      <pubDate>Mon, 08 Jun 2020 12:16:04 GMT</pubDate>
      <guid>https://www.biospace.com/cognition-therapeutics-receives-75-8-million-nia-grant-for-540-patient-phase-2-study-of-ct1812-in-collaboration-with-the-alzheimer-s-clinical-trials-consortium</guid>
    </item>
  </channel>
</rss>
